Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease (SHEEPDOG)

University of Waterloo

Status and phase: Terminated; Phase 4

Conditions: Dry Eye

Treatments: Device: iLux® system

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04159935

41401

Details and patient eligibility

About

The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype (EDE).

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Is at least 18 years of age and has full legal capacity to volunteer;

2. Has read and signed an information consent letter;

3. Is willing and able to follow instructions and maintain the appointment schedule;

4. Has been using the same CL type (brand, material and dimensions) for > 3 months;

5. Wears commercially available soft CLs on average >2 hours per day, 4-7 days per week;

6. Is willing to try to wear their habitual CLs on average ≥ 6 hours per day, 4-7 days per week and maintain this for the duration of their involvement in the study;

7. Demonstrates an acceptable lens fit of their habitual contact lenses;

8. Does not have contact lens discomfort due to contact lens fit, lens material or known solution compatibility issues, in the opinion of the investigator;

9. Has at least one month supply of their habitual contact lens products at the time of the screening visit;

10. Has a CLDEQ-8 score ≥ 12;

11. Has dry eye symptoms without CL wear (OSDI ≥ 13) and has at least one of the two following signs:

    1. Non-invasive tear break-up time (NITBUT) of < 10 seconds in at least one eye;
    2. Fluorescein staining: > 5 spots of corneal staining OR > 9 conjunctival spots OR lid wiper staining (≥ 2mm length, ≥ 25% width) in at least one eye;

12. Has a lipid layer thickness of ≤ 100 nm in both eyes;

13. A meibomian gland secretion score (MGS) of ≤ 15 for 15 glands of the lower lid in both eyes.

Exclusion criteria

1. Is participating in any concurrent clinical or research study;

2. Has used any prescription systemic medications or topical treatments for MGD or dry eye for the past 30 days prior to the screening visit and not willing to stop using these for the study duration (excluding over-the-counter artificial tears, dietary supplements and ocular lubricants but includes warm compresses, eyelid massage, eyelid hygiene, manual meibomian gland expression, punctal plug insertion or punctal occlusion, intense pulsed light treatment of the face or eyelids);

3. Has previously received treatment with an eyelid thermal pulsation device;

4. Has a history of any of the following ocular (eye or eyelid) conditions or procedures in either eye within the past 90 days prior to the screening visit:

   1. Ocular trauma
   2. Chemical burns
   3. Ocular Herpes simplex or Herpes zoster infection
   4. Limbal stem cell deficiency
   5. Recurrent ocular inflammation (e.g. uveitis, iritis, scleritis, episcleritis, keratitis)

5. Has undergone ocular surgery (e.g. intraocular, oculoplastic, corneal or refractive surgery procedure) within the past 12 months prior to the screening visit;

6. Has permanent make-up or tattoos on their eyelids;

7. Has any other known active* ocular disease and/or infection in either eye including: cicatricial lid margin disease or severe (≥ grade 3) blepharitis; moderate to severe (grade 2-4) allergic, vernal or giant papillary conjunctivitis; a hordeolum or stye; ocular surface abnormality that may compromise corneal integrity (e.g. Grade 3 corneal fluorescein staining, recurrent corneal erosion, corneal epithelial defect, map dot fingerprint dystrophy, previously treated chemical burn);

8. Has an eyelid abnormality that affects normal lid function (e.g. entropion, ectropion, oedema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis);

9. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;

10. Has any other condition that could compromise treatment or increase the risk of a procedure-related injury;

11. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;

12. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;

13. Has a history of sensitivity to rapidly blinking lights or photosensitive epilepsy;

14. Is pregnant, lactating or planning a pregnancy (by verbal communication) at the time of enrolment;

15. Is aphakic;

16. Is a member of CORE directly involved in the study;

17. Has taken part in a clinical research study within the last 30 days. * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

iLux® treatment

Experimental group

Description:

The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.

Treatment:

Device: iLux® system

Delayed iLux® treatment

Experimental group

Description:

Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.

Treatment:

Device: iLux® system